Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

Figure 4

Validation of SPRY4-IT1 expression in various cancers in TCGA cohort. The expression levels of SPRY4-IT1 in BLCA (bladder urothelial carcinoma), BRCA (breast invasion carcinoma), CHOL (cholangiocarcinoma), COAD (colon adenocarcinoma), ESCA (esophageal carcinoma), KIRC (clear cell renal cell carcinoma), GBMLGG (glioma), LIHC (liver hepatocellular carcinoma), NSCLC (non-small-cell lung cancer), OV (ovarian cancer), PAAD (pancreatic ductal adenocarcinoma), SKCM (melanoma), and STAD (stomach adenocarcinoma).